...payments to the company's Elobix AB subsidiary from HealthCare Royalty Partners (Stamford, Conn.) and the EA Pharma Co. Ltd.... ...inhibitor of solute carrier family 10 sodium-dependent bile acid transporter member 2 (SLC10A2; ASBT; IBAT). EA Pharma... ...exclusive rights to elobixibat for gastrointestinal disorders in Japan and other Asian countries from Albireo. EA Pharma...
...payments to the company's Elobix AB subsidiary from HealthCare Royalty Partners (Stamford, Conn.) and the EA Pharma Co. Ltd.... ...inhibitor of solute carrier family 10 sodium-dependent bile acid transporter member 2 (SLC10A2; ASBT; IBAT). EA Pharma... ...exclusive rights to elobixibat for gastrointestinal disorders in Japan and other Asian countries from Albireo. EA Pharma...
...Inc. (NASDAQ:ALBO). In exchange for royalties and milestones related to elobixibat and payable by the EA Pharma Co. Ltd.... ...approved in Japan to treat chronic constipation, plus up to $15 million in sales milestones. EA Pharma...
...Inc. (NASDAQ:ALBO). In exchange for royalties and milestones related to elobixibat and payable by the EA Pharma Co. Ltd.... ...if the candidate is approved in Japan, plus up to $15 million in sales milestones. EA Pharma...
...Calypso granted EA Pharma exclusive, worldwide rights to develop and commercialize preclinical candidate CALY-001 . The companies... ...disclose financial details. Calypso Biotech S.A. , Geneva, Switzerland EA Pharma Co. Ltd. , Tokyo, Japan Business: Gastrointestinal
Julian Zhu
CALY-001
EA Pharma Co. Ltd.
Calypso...
...payments to the company's Elobix AB subsidiary from HealthCare Royalty Partners (Stamford, Conn.) and the EA Pharma Co. Ltd.... ...inhibitor of solute carrier family 10 sodium-dependent bile acid transporter member 2 (SLC10A2; ASBT; IBAT). EA Pharma... ...exclusive rights to elobixibat for gastrointestinal disorders in Japan and other Asian countries from Albireo. EA Pharma...
...payments to the company's Elobix AB subsidiary from HealthCare Royalty Partners (Stamford, Conn.) and the EA Pharma Co. Ltd.... ...inhibitor of solute carrier family 10 sodium-dependent bile acid transporter member 2 (SLC10A2; ASBT; IBAT). EA Pharma... ...exclusive rights to elobixibat for gastrointestinal disorders in Japan and other Asian countries from Albireo. EA Pharma...
...Inc. (NASDAQ:ALBO). In exchange for royalties and milestones related to elobixibat and payable by the EA Pharma Co. Ltd.... ...approved in Japan to treat chronic constipation, plus up to $15 million in sales milestones. EA Pharma...
...Inc. (NASDAQ:ALBO). In exchange for royalties and milestones related to elobixibat and payable by the EA Pharma Co. Ltd.... ...if the candidate is approved in Japan, plus up to $15 million in sales milestones. EA Pharma...
...Calypso granted EA Pharma exclusive, worldwide rights to develop and commercialize preclinical candidate CALY-001 . The companies... ...disclose financial details. Calypso Biotech S.A. , Geneva, Switzerland EA Pharma Co. Ltd. , Tokyo, Japan Business: Gastrointestinal
Julian Zhu
CALY-001
EA Pharma Co. Ltd.
Calypso...